Vaccines MDPI ads

🎉 Issue 10 Cover Paper: Off-Target Effects of Recombinant Zoster Vaccine: Clinical Benefits, AS01B Adjuvant Immunobiology, and Observational Evidence Authors: Joseah Tang, Sudharshan Balaji, and Hazel H. Oon (Nanyang Technological University Singapore) We are pleased to highlight the cover paper of Vaccines Volume 14, Issue 10, a scoping review exploring the clinical benefits of the RZV (Shingrix®) that extend beyond preventing herpes zoster. 📊 Key findings: 🧠 Observational evidence links RZV administration to reduced risks of dementia, Alzheimer’s disease, and major adverse cardiological events, alongside potential geroprotective effects. 🛡️ Mechanistic studies suggest these off-target benefits may arise from VZV suppression and AS01B adjuvant-induced trained immunity via persistent monocyte reprogramming. ⚠️ Rare immune-mediated adverse events have been reported, but current evidence does not establish causality, and post-marketing surveillance supports a favorable safety profile. As clinical evidence remains observational, further research is needed to investigate the pleiotropic effects of RZV and its potential role in reducing all-cause mortality. 🔗 Read the full article: https://lnkd.in/dwxHeekh #Vaccines #Immunology #HerpesZoster #VaccineSafety #MDPI

New issue published: Vaccines, Volume 14, Issue 10 The latest issue brings together research on pressing questions in immunization science and public health. Highlights include: 🛡️ Advancing Immunization Strategies in Immunosuppressed Populations — A review of current evidence, clinical challenges, and future directions for protecting this vulnerable group. 🤰 Rethinking Evidence Generation for Vaccine Safety in Pregnancy — Calls for moving beyond randomized trials across the immunization lifecycle. 👨👩👧 Parental Attitudes Toward Childhood and Adolescent Vaccination — A study examining self-reported compliance and factors shaping vaccine acceptance. 🔗 Read the full issue: https://lnkd.in/dfpmHRcY #Vaccines #Immunization #VaccineSafety #PublicHealth #MDPI

⏰ Deadline Extended – Vaccines 2027 Travel Award Applications for the Vaccines 2027 Travel Award are now open until 30 November 2026. The award supports two junior scientists with CHF 500 each to present their research at an international conference in 2027. Eligibility: Postdoctoral fellows or PhD students planning to attend an international conference in 2027 (oral or poster presentation). Required documents: 🗓️ Conference information and abstract 📄 CV and publication list ✍️ Justification letter (max. 800 words) 📝 Recommendation letter from your supervisor Apply here: https://lnkd.in/eD2asrRk #Vaccines #MDPI #TravelAward #EarlyCareer #Vaccinology #AcademicOpportunity

🧬 Issue 9 Cover Paper – From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines Author: Sarfaraz K. Niazi This framework proposes seven sequential gates for antigen-defined, HLA-restricted T-cell vaccines: tumor specificity, peptide–HLA presentation, population coverage, persistence, selective T-cell recognition, manufacturability, and randomized clinical benefit. 🧬 Architecture: pre-manufactured shared antigen core + personalized shell when needed 📊 Evidence: mRNA neoantigen therapy + pembrolizumab showed RFS signal in phase 2b melanoma; a 20-antigen shared cassette induced TP53—not KRAS—responses 🔬 Four falsifiable predictions defined for future experiments 📝 Conclusion: a research agenda, not a validated decision tool 📖 Open access: https://lnkd.in/esQmd68W #MDPI #Vaccines #CancerVaccines #Immunotherapy #CoverPaper

🏆 Highly Cited Paper – Challenges and Limitations of Current RSV Prevention Strategies in Infants and Young Children Authors: Nicola Principi, Serafina Perrone, Susanna Esposito RSV remains a leading cause of lower respiratory tract infections and hospitalizations in infants and young children globally. Recent advances—nirsevimab and maternal RSV preF vaccination—have improved early protection, but significant limitations remain. 📉 Protection wanes after 6 months, yet nearly half of RSV‑related deaths occur in children over 6 months old ⚠️ Maternal vaccine efficacy is uncertain in very‑preterm infants; safety concerns persist (preterm birth, GBS, hypertensive disorders) 🌍 Real‑world data from low‑income countries are lacking, limiting generalizability 🧬 The unconfirmed risk of vaccine‑associated enhanced disease (VAED) has delayed pediatric vaccine development 🔬 Emerging monoclonal antibodies and live‑attenuated vaccines are under investigation to extend protection beyond infancy The authors call for next‑generation vaccines, enhanced pharmacovigilance, and equitable global implementation. 📖 Open access: 🔗 https://lnkd.in/eXvMtzbY #MDPI #Vaccines #RSV #InfantHealth #HighlyCited #PublicHealth

🧬 Newsletter Featured Article – Current Status of Vaccines for Porcine Reproductive and Respiratory Syndrome: Interferon Response, Immunological Overview, and Future Prospects Authors: Jiuyi Li, Laura Miller and Yongming Sang Porcine reproductive and respiratory syndrome (PRRS) remains a formidable challenge for the global pig industry. Caused by PRRS virus (PRRSV), this disease primarily affects porcine reproductive and respiratory systems, undermining effective host interferon and other immune responses, resulting in vaccine ineffectiveness. Key insights: 🧬 Currently available vaccines: modified live virus (MLV) and killed virus (KV) vaccines 💉 Live vaccines offer enhanced protective effectiveness but modest cross‑protection 🛡️ Inactivated vaccines are safer but limited in protective efficacy 🔬 Review updates knowledge on PRRS vaccines’ interactions with the host interferon system 📊 Presents strengths and weaknesses of both vaccine types 📖 Open access: 🔗 https://brnw.ch/21x6apw #MDPI #Vaccines #PRRS #VeterinaryVaccines #Newsletter